A 24‑week telehealth program that gave people tirzepatide (or semaglutide) along with a virtual coaching plan helped participants lose an average of 12% of their body weight, drop their blood pressure, and eat and move better, with fewer side‑effects than typical clinical trials.

Limited data exist on telemedicine prescribing of semaglutide and tirzepatide. The effects of a telehealth obesity management program combining the provision of semaglutide and tirzepatide with a behavioral program tailored for long-acting antiobesity medications (AOMs) were evaluated. In this single-arm study, 180 participants recruited from a telehealth medical obesity program received a virtual behavioral program tailored for long-acting AOMs, Bluetooth wireless scales, and a blood pressure (BP) cuff. Participants' (mean age = 44.1; 91% female; 81% White; mean weight = 102.8 kg) weight, BP, eating habits, dietary quality, physical activity, and side effects were assessed at baseline and at 12 and 24 weeks. Wilcoxon rank sum tests were conducted, and p values were adjusted using a false discovery rate approach. Intent-to-treat analysis was performed using last observation carried forward (LOCF). Weight loss was 7.2% (SD = 5.2%) at 12 weeks and 12.3% (SD = 6.9%) at 24 weeks (p < 0.0001). Mean BP declined from 131.0/83.8 (SD = 17.2/12.2) to 122.5/78.7 (SD = 13.7/10.1) at 12 weeks and 120.0/78.2 (SD = 13.5/10.6) at 24 weeks (p < 0.0001). Participants significantly improved their eating habits, diet quality, and activity. Side effects were markedly lower than in previously reported trials. Virtually delivered treatment combining telemedicine and a behavioral program tailored for long-acting AOMs demonstrated clinically significant improvements in weight, BP, diet, and activity over 24 weeks. ClinicalTrials.gov identifier: NCT06034457.